Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients - Full Text View

Purpose

To evaluate the efficacy and safety of switching from Retrovir to Tenofovir or Abacavir in HIV-infected patients

Condition	Intervention	Phase
HIV Infections	Drug: Tenofovir disoproxil fumarate Drug: Abacavir	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Efficacy and Safety of Switching From AZT to Tenofovir

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS

Drug Information available for: Abacavir Tenofovir Abacavir sulfate Tenofovir Disoproxil Fumarate

U.S. FDA Resources

Further study details as provided by University of Aarhus:

Primary Outcome Measures:

Renal function measured by Cystatin-C and creatinine clearance [ Time Frame: Weeks 0, 4, 8, 12, 24, 24, 48, 96 ] [ Designated as safety issue: Yes ]
Levels of renal tubule function markers in blood and urine [ Time Frame: Weeks 0, 12, 24, 48, 96 ] [ Designated as safety issue: Yes ]
Bone mass assessed by DEXA [ Time Frame: Weeks 0, 24, 48, 96 ] [ Designated as safety issue: Yes ]
Levels of bone turnover markers in blood and urine [ Time Frame: Weeks 0, 12, 24, 48, 96 ] [ Designated as safety issue: Yes ]
Insulin resistance [ Time Frame: Weeks 0, 12, 24, 48, 96 ] [ Designated as safety issue: Yes ]
Changes in body composition assessed by patient questionnaire and standardized examination by physician [ Time Frame: Weeks 0, 12, 24, 48, 96 ] [ Designated as safety issue: Yes ]
Changes in subcutaneous adipose tissue assessed by DEXA [ Time Frame: Week 0, 24, 48, 96 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Patients with viral load < 40 copies/ml [ Time Frame: Weeks 0, 4, 8, 12, 24, 48, 96 ] [ Designated as safety issue: Yes ]
CD-4 cell count [ Time Frame: Weeks 0, 4, 8, 12, 24, 48, 96 ] [ Designated as safety issue: Yes ]
Fasting triglycerides, HDL and LDL [ Time Frame: Weeks 0, 12, 24, 48, 96 ] [ Designated as safety issue: Yes ]
Development of resistance mutations [ Time Frame: Weeks 0, 12, 24, 48, 96 ] [ Designated as safety issue: Yes ]
Development of adverse events and serious adverse events [ Time Frame: Weeks 0, 4, 8, 12, 24, 48, 96 ] [ Designated as safety issue: Yes ]


Enrollment:	40
Study Start Date:	June 2008
Study Completion Date:	August 2010
Primary Completion Date:	August 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: 1 Tenofovir	Drug: Tenofovir disoproxil fumarate Tenofovir disoproxil 245 mg oral tablet once daily
Active Comparator: 2 Abacavir	Drug: Abacavir Abacavir 300 mg oral tablet twice daily

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

HIV-infection with undetectable viral load
Antiretroviral treatment including Retrovir for more than three months
If fertile female: Negative pregnancy test and use of safe contraception
Negative HBs-antigen titer

Exclusion Criteria:

Prior treatment with abacavir or tenofovir
Resistance towards abacavir or tenofovir
Tissue type HLA-B5701
Renal disease
Diabetes Mellitus
Osteoporosis
Pregnant or lactating subjects
Intravenous drug abuse
Hypersensitivity towards drugs or active ingredient used
ALAT > 5 times upper normal level
Current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00647244

Locations


Denmark
Aarhus University Hospital
Århus N, Denmark, 8200

Sponsors and Collaborators

Aarhus University Hospital

More Information

No publications provided by University of Aarhus

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, Østergaard L, Langdahl BL, Laursen AL. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One. 2012;7(3):e32445. doi: 10.1371/journal.pone.0032445. Epub 2012 Mar 29.

Rasmussen TA, Tolstrup M, Melchjorsen J, Frederiksen CA, Nielsen US, Langdahl BL, Østergaard L, Laursen AL. Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis. 2011 Oct 4;11:267. doi: 10.1186/1471-2334-11-267.


Responsible Party:	Alex Lund Laursen, MD, PhD, DmSC, Department of Infectious Diseases, Aarhus University Hospital, Denmark
ClinicalTrials.gov Identifier:	NCT00647244 History of Changes
Other Study ID Numbers:	SKS-HIV-002, EudraCT2007-004372-39
Study First Received:	March 26, 2008
Last Updated:	December 17, 2010
Health Authority:	Denmark: Danish Medicines Agency

Keywords provided by University of Aarhus:


Tenofovir Abacavir Antiretroviral therapy HIV Nucleoside analogue reverse transcriptase inhibitor

Additional relevant MeSH terms:


Abacavir Tenofovir Tenofovir disoproxil Anti-HIV Agents Anti-Infective Agents Anti-Retroviral Agents Antiviral Agents	Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors Pharmacologic Actions Reverse Transcriptase Inhibitors Therapeutic Uses

ClinicalTrials.gov processed this record on March 02, 2015

Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients (SWAP)